All In Biotech

Drug Trial Radar · NCT06968962

Comparison of Sequential to Initial Combination Therapy in PAH

A Multicenter, Randomized, Controlled, Double-blind, and Non-inferiority Clinical Trial to Compare the Efficacy of Sequential to Initial Combination Therapy in Patients With Pulmonary Arterial Hypertension

Last checked: Nov 20, 2026Latest source record: Jul 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 376 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

376

Planned (sponsor's estimate)

Start

May 14, 2025

Primary completion

May 2028

Study completion Dec 2028

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Huzhou Central Hospital; Ningbo Medical Center Lihuili Hospital; First Affiliated Hospital of Ningbo University; Ningbo No.2 Hospital; Affiliated Hospital of Jiaxing University; The Second Affiliated Hospital of Jiaxing University; First Affiliated Hospital of Wenzhou Medical University; Shanghai Pulmonary Hospital, Shanghai, China; Taizhou Hospital; Guangdong Provincial People's Hospital
First posted
May 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, controlled, double-blind, and non-inferiority clinical trial to compare the efficacy of sequential to initial combination therapy in patients with pulmonary arterial hypertension (PAH). Ambrisentan and Tadalafil will be used in the study. Our research hypothesis is that the efficacy of sequential combination therapy in PAH patients is not inferior to the initial combination therapy as the primary efficacy endpoint is the change in 6MWD at month 12 from baseline.

Conditions

  • Pulmonary Arterial Hypertension (PAH)

Interventions

  • TadalafilDrug

    Target dose 40 mg OD

  • AmbrisentanDrug

    Target dose 10 mg OD

  • Ambrisentan mimicDrug

    Ambrisentan mimic will switch to Ambrisentan if low risk status was not achived at month 4, or 8, or 12.

  • Tadalafil mimicDrug

    Tadalafil mimic will switch to Tadalafil if low risk status was not achived at month 4, or 8, or 12.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change of 6MWD at month 12 from baselineTime frame: Baseline and Month 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.